Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

What's in Store for AstraZeneca (AZN) This Earnings Season?

The company’s earnings beat estimates in each of the past four quarters with the average surprise being 36.96%. AstraZeneca PLC Price and EPS Surprise. AstraZeneca PLC price-eps-surprise | AstraZeneca PLC Quote. In the last reported quarter, AstraZeneca delivered a positive earnings surprise of 11.11%. Product sales in the third quarter benefited from favorable inventory and gross-to-net movements. However, the benefits were absent this time around. Fourth-quarter sales of Imfinzi are likely to have benefited from strong demand trends in the United States, especially in lung cancer indications. AstraZeneca’s other major drugs like Fasenra, Brilinta and Farxiga are likely to have contributed to sales growth the soon-to-be reported quarter. However, please note that increased competition and formulary plan changes for competitors’ drugs hurt sales of Farxiga in the United States in the third quarter.

First found on: www.nasdaq.com And then on: 1 other references